Restoring one brain protein improved memory and balance in old mice within 30 days

Mice that were 20 months old got thicker skin, denser bones, sharper memory and steadier balance within 30 days of having a single brain protein put back. The protein is Menin, and the experiment came from Lige Leng’s group at Xiamen University in China. A summary of the work resurfaced on ScienceDaily in October 2026, which is why the result is circulating again.

The underlying paper is older than the recent attention suggests. It appeared in PLOS Biology in 2023 titled “Hypothalamic Menin regulates systemic aging and cognitive decline,” and everything in it was done in mice. That limit matters for every claim below, because nothing here has been tested in a person.

What Menin does in the hypothalamus

Menin is a protein that helps restrain inflammation in the hypothalamus, the small brain region that governs body temperature, hunger, metabolism, sleep and hormone release. It also takes part in controlling which genes are switched on. According to the ScienceDaily write-up of the study, the team measured Menin across the lifespan and found that levels fall with age in certain hypothalamic neurons, while astrocytes and microglia, two other brain cell types, did not show the same drop.

To test whether the decline was a bystander or a driver, the researchers did the reverse experiment as well. They engineered mice in which Menin could be selectively disabled. Those animals developed more inflammation in the hypothalamus, thinner skin, reduced bone mass, worse performance on cognitive tests and modestly shorter lifespans, a cluster of changes that resembles ordinary aging arriving early.

The rescue experiment in 20-month-old mice

The central result came from the opposite direction. Using a gene-delivery technique, the team raised Menin in the ventromedial hypothalamus of mice aged 20 months. Thirty days later the animals had thicker skin, higher bone mass and better scores on learning, memory and balance tests, and inflammation in the region had dropped. The summary does not say which viral vector carried the gene, so how the delivery was done cannot be assessed from it. Neuroscience News reports the same set of improvements, and Genetic Engineering & Biotechnology News covered the paper when it first appeared in March 2023 and says the treated mice also lived longer.

Leng, who led the work at Xiamen University, framed the finding broadly. In the group’s account, restoring Menin in the ventromedial hypothalamus “reversed aging-related phenotypes,” and the group suggested that Menin “may be the key protein connecting the genetic, inflammatory, and metabolic factors of aging.” The claim is about specific measurable markers in mice, such as bone mass and results on learning and memory tests, not about aging as a whole.

The location matters for why a single protein could touch so many tissues. The hypothalamus sits at the junction of the brain and the body’s hormonal and metabolic systems, so inflammation there can plausibly ripple outward to bone, skin and the circuits that handle memory. That is the logic behind the group’s title, which calls the region’s Menin a regulator of systemic aging rather than just brain aging. The experiments are consistent with that idea, though they were not designed to prove every link in the chain.

D-serine and the memory pathway

The memory gains appear to run through a chemical chain. Losing Menin reduced an enzyme called PHGDH, which sits in the pathway that makes serine, and that in turn lowered levels of D-serine in the brain. When Menin was restored, D-serine in the hippocampus, the structure central to forming memories, rose again. The authors then gave older mice D-serine in their drinking water for three weeks. Learning and memory improved, but bone and skin did not.

That split is informative. It implies Menin acts through more than one route, with D-serine explaining the cognitive part and other mechanisms presumably handling the skin and bone changes. Leng described D-serine as “a potentially promising therapeutic for cognitive decline,” a sentence that is also carefully conditional. The full paper is open access through its DOI record, and the journal also hosts it on the PLOS Biology site.

What mouse data cannot say about people

The caveats are substantial. It is unclear why Menin declines with age in the first place, how long the benefits last after treatment, and whether raising it produces unwanted effects elsewhere in the body. The ScienceDaily summary also points out that human evidence for D-serine is thin: a 2016 trial in 50 healthy older adults found improvement on only one spatial learning test, and animal work has raised kidney-safety concerns at high doses.

There is also the matter of what counts as success. A 30-day readout is short, and the summary cites a separate survival analysis in which Menin-treated mice outlived untreated controls, but it does not report how large that difference was. Without the effect size, durability and any side effects measured over months, the result reads as a strong proof of principle in a controlled animal setting and nothing more.

A later study of Alzheimer’s-model mice, published in April 2025, found that early increases in D-serine coincided with disrupted brain signaling, which suggests the compound’s effect depends on timing and context. The same summary calls D-serine experimental rather than a proven treatment. For readers tempted by supplements, that is the operative sentence: the mouse result is a mechanism to follow, and no dosing guidance for people comes out of it.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview